In a landmark development for the talc scandal, The Lancet has retracted a 1977 paper that argued against testing cosmetic talc for asbestos — after historians discovered its author was a paid Johnson & Johnson consultant who gave the company editorial control.
What Happened
On 25 March 2026, The Lancet retracted an unsigned commentary published in 1977. The paper, titled "Cosmetic talc," argued there was no reason to believe cosmetic talc use could lead to cancer. It opposed government-mandated regulatory testing for asbestos in cosmetic talc products. For nearly 50 years, this paper was cited as evidence supporting the safety of talc-based consumer products. The retraction came after the journal learned of an undisclosed conflict of interest.
The Hidden Author
The commentary was written by Francis J C Roe, a prominent cancer researcher. Roe was, at the time, a paid consultant to Johnson & Johnson — then the world's leading producer of talc products. This financial relationship was not disclosed to The Lancet's editors when the paper was submitted. Roe gave J&J an advance copy of the manuscript before publication. He incorporated the company's editorial suggestions into the final version. The paper was published unsigned, concealing Roe's identity and his industry ties.
How It Was Discovered
Public health historians David Rosner of Columbia University and Gerald Markowitz uncovered the connection. They found evidence in documents obtained through discovery in lawsuits against Johnson & Johnson. In December 2025, they wrote to The Lancet presenting their findings. The Lancet confirmed the conflict of interest and issued the retraction in March 2026. Both historians have served as expert witnesses in asbestos-related litigation.
Why It Matters for the Talc Scandal
The 1977 paper shaped regulatory and public understanding of talc safety for decades. It was used to argue against stricter testing requirements for asbestos in consumer talc. The retraction reveals how corporate influence may have shaped the scientific narrative around talc safety. It fits a broader pattern: J&J has faced allegations that it knew about asbestos contamination in its products from the 1960s but continued to market them as safe. J&J paid $700 million to 43 US states in 2025 over misleading marketing about product safety. Over 90,000 lawsuits have been filed against the company worldwide.
Implications for UK Claimants
The retraction strengthens the position of claimants pursuing talcum powder claims in the UK. It undermines a piece of evidence that was historically cited in defence of talc safety. Jones Whyte, which is leading the first Scottish group action against J&J in the Court of Session, will be monitoring how this development affects proceedings. Claimants and their legal teams can point to this as further evidence of corporate efforts to suppress the truth about contamination risks. If you believe you may have been affected, it is important to seek legal advice promptly — limitation periods apply.
For more information about the Scottish group action or to discuss a potential claim, contact Jones Whyte.
Disclaimer: This article is for informational purposes only and should not be construed as legal advice. Please consult with a qualified legal professional for advice specific to your circumstances.